Get started
Author

María Valero

Observed names: M. Valero, Maria Valero
ORCID: 0000-0002-2539-5710
Observed ORCID: 0000-0002-2539-5710
OpenAlex ID: A5112514713
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial
2025 · Matthias Preusser, Javier Garde-Noguera, et al. · Nature Medicine · 32
PDF
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
2025 · Rupert Bartsch, Maximilian Marhold, et al. · The Lancet Oncology · 20
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
2025 · Thorsten Fuereder, Javier Garde-Noguera, et al. · The Lancet Oncology · 19
Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain
2011 · José María Vieitez, Rocío García-Carbonero, et al. · Clinical & Translational Oncology · 5
Patritumab deruxtecan (HER3-DXd) in active brain metastases (BM) from metastatic breast (mBC) and non–small cell lung cancers (aNSCLC), and leptomeningeal disease (LMD) from advanced solid tumors: Results from the TUXEDO-3 phase II trial.
2025 · Matthias Preusser, Javier Garde, et al. · Journal of Clinical Oncology · 4
PDF
Abstract PO2-19-05: Randomized Phase II trial evaluating three anti-diarrhoeal prophylaxis strategies in patients with HER2+/HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM/2018-06)
2024 · Miguel Gil-Gil, Miguel Martín, et al. · Cancer Research · 3
Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC).
2013 · Javier Salvador, Manuel Ruiz Borrego, et al. · Journal of Clinical Oncology · 2
Abstract PD13-10: Outcome of patritumab deruxtecan (HER3-DXd) in patients with HER2-positive metastatic breast cancer and CNS involvement previously treated with T-DXd: A subanalysis of TUXEDO-3
2026 · R. Bartsch, A. Llombart-Cussac, et al. · Clinical Cancer Research
Clinical outcomes and subsequent therapy in patients with platinum-sensitive recurrent ovarian cancer deriving long-term benefit from maintenance niraparib: a subgroup analysis of the GEICO-88R study
2025 · Juan F. Cueva, Isabel Palacio, et al. · International Journal of Gynecological Cancer
Works count: 9
Citation count: 85
H-index: 4
I10-index: 3
Year
Topic
Type